SageView Advisory Group’s Theriva Biologics TOVX Stock Holding History

SageView Advisory Group’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-417	Closed	-$1M	–	767
2024 Q1	$1M	Buy	+417	New	+$4.88K	0.05%	198

Other funds holding TOVX

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

SageView Advisory Group's TOVX Position: Q2 2024 in Review

SageView Advisory Group sold out of Theriva Biologics (TOVX) in Q2 2024, closing a stake of 417 shares — an estimated $1M sold.

SageView Advisory Group first reported a position in TOVX in Q1 2024 and held it in 1 quarter. The position peaked at $1M in Q1 2024. 20 funds tracked by Wall St. Rank hold TOVX as of Q2 2024.

SageView Advisory Group reported no remaining Theriva Biologics position as of Q2 2024 after selling out during the quarter.
SageView Advisory Group sold 417 Theriva Biologics shares in Q2 2024, an estimated $1M.
SageView Advisory Group first reported a position in Theriva Biologics in Q1 2024 and held it in 1 quarter.
SageView Advisory Group's Theriva Biologics position peaked at $1M in Q1 2024.
20 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2024.

Based on SageView Advisory Group's 13F filing for Q2 2024, filed 12 Aug 2024.